Someone posted a link to the full text. Looks like their main point is that for most people with diabetes (who have type 2), insulin of any form isn’t the best first line treatment, things like glp-1 receptor agonists (e.g., ozempic) work way better, but since it’s not “insulin” it’s not covered.
I’m guessing the editors of the Atlantic gave it the original bad headline, cause it seems like the author is genuine.
The fact they changed the headline is itself praiseworthy, but the fact it was click bait and sensationalist to begin counters it.
The point about making the older stuff cheaper is something that isn’t mentioned as much as it should be in these debates.
Ultimately even if the older stuff is worse and requires more attention and monitoring (less convenient), it is still better than nothing.
Someone posted a link to the full text. Looks like their main point is that for most people with diabetes (who have type 2), insulin of any form isn’t the best first line treatment, things like glp-1 receptor agonists (e.g., ozempic) work way better, but since it’s not “insulin” it’s not covered.
I’m guessing the editors of the Atlantic gave it the original bad headline, cause it seems like the author is genuine.
So the physician cares about patient wellbeing while the newspaper cares about engagement? Sounds about right